SCM
RCKT icon

Sio Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Sio Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-181,725
Closed -$1.45M – 68
2017
Q1 		$1.45M Buy
+181,725
New +$1.22M 0.81% 31

Other funds holding RCKT

RCP
Rho Capital Partners New York $20.4M AUM
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Sio Capital Management's RCKT Position: Q2 2017 in Review

Sio Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2017, closing a stake of 181,725 shares — an estimated $1.45M sold.

Sio Capital Management first reported a position in RCKT in Q1 2017 and held it in 1 quarter. The position peaked at $1.45M in Q1 2017. 51 funds tracked by Wall St. Rank hold RCKT as of Q2 2017.

  • Sio Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Sio Capital Management sold 181,725 Rocket Pharmaceuticals shares in Q2 2017, an estimated $1.45M.
  • Sio Capital Management first reported a position in Rocket Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Sio Capital Management's Rocket Pharmaceuticals position peaked at $1.45M in Q1 2017.
  • 51 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2017.

Based on Sio Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.